<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04085653</url>
  </required_header>
  <id_info>
    <org_study_id>CBYL719F12001M</org_study_id>
    <nct_id>NCT04085653</nct_id>
  </id_info>
  <brief_title>Managed Access Program (MAP) to Provide Access to Alpelisib (BYL719) for Patients With PIK3CA-Related Overgrowth Spectrum (PROS)</brief_title>
  <official_title>Managed Access Program (MAP) to Provide Access to Alpelisib (BYL719) for Patients With PIK3CA-Related Overgrowth Spectrum (PROS)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Novartis Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Novartis</source>
  <brief_summary>
    <textblock>
      The purpose of this Cohort Treatment Plan is to allow access to alpelisib for patients&#xD;
      diagnosed with PIK3CA-Related Overgrowth Spectrum (PROS) who fulfill certain eligibility&#xD;
      criteria as specified in this document. The patient's Treating Physician should follow the&#xD;
      suggested treatment guidelines and comply with all local health authority regulations&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Available</overall_status>
  <study_type>Expanded Access</study_type>
  <has_expanded_access>No</has_expanded_access>
  <expanded_access_info>
    <expanded_access_type_treatment>Yes</expanded_access_type_treatment>
  </expanded_access_info>
  <condition>PIK3CA-Related Overgrowth Spectrum (PROS)</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>alpelisib</intervention_name>
    <description>Alpelisib will be provided as 50 mg, 125mg and 200 mg film coated tablets as individual patient supply, and will be dosed on a flat scale of mg/day not to be adjusted to body weight or surface area.&#xD;
In Adult patients, alpelisib will be administered at a starting dose of 250 mg orally once daily on a continuous dosing schedule and can be adjusted for toxicity per the recommendations in this treatment plan.&#xD;
In Pediatric patients, alpelisib will be administered at a maximum starting dose of 50 mg orally once daily on a continuous dosing schedule and can be interrupted for toxicity per the recommendations in this treatment plan; no dose reductions are allowed.</description>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Patients eligible for inclusion in this Treatment Plan have to meet all of the following&#xD;
        criteria:&#xD;
&#xD;
          1. Adult or pediatric patients ≥ 2 years of age, with a diagnosis of PROS preferably with&#xD;
             evidence of a mutation in the PIK3CA gene.&#xD;
&#xD;
          2. The treating physician has determined that the patient's condition is severe or life&#xD;
             threatening, treatment is necessary and there are no other feasible alternatives for&#xD;
             the patient.&#xD;
&#xD;
          3. Confirmed adequate bone marrow function. Written patient informed consent must be&#xD;
             obtained prior to start of treatment.&#xD;
&#xD;
        Exclusion criteria&#xD;
&#xD;
        Patients eligible for this Treatment Plan must not meet any of the following criteria:&#xD;
&#xD;
          1. Patient has history of hypersensitivity to any drugs or metabolites of PI3K inhibitor&#xD;
             or any of the excipients of alpelisib.&#xD;
&#xD;
          2. Patient with uncontrolled diabetes mellitus Type I or not controlled type II (based on&#xD;
             FPG and HbA1c, see inclusion criterion 2)&#xD;
&#xD;
          3. Patient who has other concurrent severe and/or uncontrolled medical conditions that&#xD;
             would, in the Treating Physician's judgment, contraindicate administration of&#xD;
             alpelisib (eg. active or uncontrolled severe infection, chronic active hepatitis,&#xD;
             immuno-compromised, acute or chronic pancreatitis, uncontrolled high blood pressure,&#xD;
             interstitial lung disease, etc.)&#xD;
&#xD;
          4. Patient has a known history of severe cutenaous reactions like Steven Johnson's&#xD;
             syndrome, erythema multiforme, toxic epidermal necrolysis or drug reaction with&#xD;
             eosinophilia and systemic symptoms.&#xD;
&#xD;
          5. History of pancreatitis within 1 year of screening or past medical history of chronic&#xD;
             pancreatitis.&#xD;
&#xD;
          6. Subject with child pugh score B or C.&#xD;
&#xD;
          7. Subjects with unresolved osteonecrosis of the jaw.&#xD;
&#xD;
          8. Subject is currently receiving any of the following medications and cannot be&#xD;
             discontinued 7 days prior to the start of the treatment: Strong inducers of CYP3A4,&#xD;
             Inhibitors of BCRP.&#xD;
&#xD;
          9. Patient has a known history of Human Immunodeficiency Virus (HIV) infection (testing&#xD;
             not mandatory unless required by local regulations or requirements).&#xD;
&#xD;
         10. Patient who is concurrently being treated with drugs known to be strong inhibitors or&#xD;
             inducers of the isoenzyme CYP3A; switching to different medications prior to start of&#xD;
             program treatment is allowed within the last 5 days prior to starting program&#xD;
             treatment&#xD;
&#xD;
         11. Patient is currently receiving or has received systemic corticosteroids ≤ 2 weeks&#xD;
             prior to start of program treatment, or who have not fully recovered from side effects&#xD;
             of such treatment.&#xD;
&#xD;
             Note: The following uses of corticosteroids are permitted: single doses, topical&#xD;
             applications (e.g., for rash), inhaled sprays (e.g., for obstructive airways&#xD;
             diseases), eye drops or local injections (e.g., intra-articular).&#xD;
&#xD;
         12. Male patient who does not apply highly effective contraception during the treatment&#xD;
             with alpelisib and through the duration as defined below after the final dose of&#xD;
             alpelisib. Sexually active males should use a condom during intercourse while taking&#xD;
             drug and for at least 4 weeks after stopping alpelisib and should not father a child&#xD;
             in this period. A condom is required to be used also by vasectomized men in order to&#xD;
             prevent delivery of the drug via seminal fluid.&#xD;
&#xD;
         13. Subject is not able to understand and to comply with treatment instructions and&#xD;
             requirements&#xD;
&#xD;
         14. Subject is a nursing (lactating) or pregnant woman as confirmed by a positive serum&#xD;
             (hCG) test prior to initiating study treatment&#xD;
&#xD;
         15. Subject is a woman of child-bearing potential defined as all women physiologically&#xD;
             capable of becoming pregnant, unless they are using highly effective methods of&#xD;
             contraception during study treatment and at least for 1 week after the last dose of&#xD;
             any study treatment. Highly effective contraception methods include:&#xD;
&#xD;
               -  Total abstinence (when this is in line with the preferred and usual lifestyle of&#xD;
                  the subject ). Periodic abstinence (e.g., calendar, ovulation, symptothermal,&#xD;
                  post-ovulation methods) and withdrawal are not acceptable methods of&#xD;
                  contraception. Female sterilization (have had surgical bilateral oophorectomy&#xD;
                  with or without hysterectomy), total hysterectomy or bilateral tubal ligation at&#xD;
                  least 6 weeks before taking study treatment. In case of oophorectomy alone, only&#xD;
                  when the reproductive status of the woman has been confirmed by follow up hormone&#xD;
                  level assessment&#xD;
&#xD;
               -  Male sterilization (at least 6 months prior to screening). For female subjects on&#xD;
                  the study the vasectomized male partner should be the sole partner for that&#xD;
                  subject&#xD;
&#xD;
               -  Use of oral (estrogen and progesterone), injected or implanted combined hormonal&#xD;
                  method of contraception or placement of an intrauterine device (IUD) or&#xD;
                  intrauterine system (IUS), or forms of hormonal contraception that have&#xD;
                  comparable efficacy (failure rate &lt;1%), for example hormonal vaginal ring or&#xD;
                  transdermal hormone contraception. In case of use or oral contraception, women&#xD;
                  should have been stable on the same pill for a minimum of 3 months before taking&#xD;
                  study treatment.&#xD;
&#xD;
             Note: Women are considered postmenopausal and not of child bearing potential if they&#xD;
             have had 12 months of natural (spontaneous) amenorrhea with an appropriate clinical&#xD;
             profile (i.e., age appropriate, history of vasomotor symptoms) or have had surgical&#xD;
             bilateral oophorectomy (with or without hysterectomy), total hysterectomy, or&#xD;
             bilateral tubal ligation at least 6 weeks before taking study treatment. In the case&#xD;
             of oophorectomy alone, only when the reproductive status of the woman has been&#xD;
             confirmed by follow up hormone level assessment is she considered not of child bearing&#xD;
             potential.&#xD;
&#xD;
         16. Subject is a sexually active male unwilling to use a condom during intercourse while&#xD;
             taking study treatment, and for 1 week or 4 weeks after stopping aleplisib. A condom&#xD;
             is required for all sexually active male participants to prevent them from fathering a&#xD;
             child AND to prevent delivery of study treatment via seminal fluid to their partner.&#xD;
             In addition, male participants must not donate sperm during study and up to the time&#xD;
             period specified above.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>2 Years</minimum_age>
    <maximum_age>99 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Novartis Pharmaceuticals</last_name>
    <phone>1-888-669-6682</phone>
    <email>novartis.email@novartis.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Novartis Pharmaceuticals</last_name>
    <phone>+41613241111</phone>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Arkansas Children's Hospital</name>
      <address>
        <city>Little Rock</city>
        <state>Arkansas</state>
        <zip>72202</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Available</status>
    <contact>
      <phone>501-320-3755</phone>
    </contact>
    <investigator>
      <last_name>Janna Journeycake</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Children's Hospital Los Angeles Childen's Center for Cancer</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90027</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Available</status>
    <contact>
      <phone>323-361-2212</phone>
    </contact>
    <investigator>
      <last_name>Fariba Navid</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Children's Hospital Los Angeles</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90027</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Available</status>
    <contact>
      <phone>323-660-2450</phone>
    </contact>
    <investigator>
      <last_name>Diana Moke</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Children's Hospital Los Angeles</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90027</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Available</status>
    <contact>
      <phone>323-669-2501</phone>
    </contact>
    <investigator>
      <last_name>Fariba Navid</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>UCLA Medical Center</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90095</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Available</status>
    <investigator>
      <last_name>Vivian Y Chang</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of California at Los Angeles</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90095</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Available</status>
    <investigator>
      <last_name>Vivian Y Chang</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Children's Specialists of San Diego Medical Group</name>
      <address>
        <city>San Diego</city>
        <state>California</state>
        <zip>92123</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Available</status>
    <contact>
      <phone>858-966-8153</phone>
    </contact>
    <investigator>
      <last_name>Deborah Schiff</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Rady Children s Hospital Sickle Cell Disease Center</name>
      <address>
        <city>San Diego</city>
        <state>California</state>
        <zip>92123</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Available</status>
    <contact>
      <phone>858-966-5811</phone>
    </contact>
    <investigator>
      <last_name>Deborah Schiff</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Rady Childrens Hospital</name>
      <address>
        <city>San Diego</city>
        <state>California</state>
        <zip>92123</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Available</status>
    <investigator>
      <last_name>Deborah Schiff</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Alfred I DuPont Hospital for Children</name>
      <address>
        <city>Wilmington</city>
        <state>Delaware</state>
        <zip>19899</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Available</status>
    <contact>
      <phone>302-651-5804</phone>
    </contact>
    <investigator>
      <last_name>Andrew Walter</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Emory University School of Medicine/Winship Cancer Institute</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30322</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Available</status>
    <contact>
      <phone>404-778-3126</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>University of Iowa Health Care Dept of Pediatrics &amp; Pulmonary</name>
      <address>
        <city>Iowa City</city>
        <state>Iowa</state>
        <zip>52242</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Available</status>
    <contact>
      <phone>319-356-7883</phone>
    </contact>
    <investigator>
      <last_name>Theodosia Thoma</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Boston Childrens Hospital Pediatric Heamatology Oncology</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02215</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Available</status>
    <contact>
      <phone>267-425-3010</phone>
    </contact>
    <investigator>
      <last_name>Whitney Eng</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Children's Hospital and Clinics of Minnesota Childrens Hosp/Clinic</name>
      <address>
        <city>Minneapolis</city>
        <state>Minnesota</state>
        <zip>55404</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Available</status>
  </location>
  <location>
    <facility>
      <name>Atlantic Medical Group</name>
      <address>
        <city>Morristown</city>
        <state>New Jersey</state>
        <zip>07960</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Available</status>
    <investigator>
      <last_name>Michael Scola</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Roswell Park Cancer Institute Pediatrics</name>
      <address>
        <city>Buffalo</city>
        <state>New York</state>
        <zip>14263</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Available</status>
    <investigator>
      <last_name>Steven Ambrusko</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Cohen Children's Medical Center of New York</name>
      <address>
        <city>New Hyde Park</city>
        <state>New York</state>
        <zip>11040</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Available</status>
    <contact>
      <phone>718-470-3493</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>NYU Langone Health</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10016</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Available</status>
    <investigator>
      <last_name>Elisabeth A. Raetz</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>NYU Laura and Isaac Perlmutter Cancer Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10016</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Available</status>
    <contact>
      <phone>212-263-9959</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Mission Hospital</name>
      <address>
        <city>Asheville</city>
        <state>North Carolina</state>
        <zip>28801</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Available</status>
    <investigator>
      <last_name>Krystal Bottom</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Cincinnati Children's Hospital Medical Center Cancer &amp; Blood Disease Inst.</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>45229-3039</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Available</status>
    <contact>
      <phone>513-803-1140</phone>
    </contact>
    <investigator>
      <last_name>Adrienne Hammill</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Cincinnati Children's Hospital Medical Center</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>45229-3039</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Available</status>
    <investigator>
      <last_name>Philippe Backeljauw</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Children's Hospital Medical Center</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>45229</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Available</status>
    <contact>
      <phone>513-636-4955</phone>
    </contact>
    <investigator>
      <last_name>Adrienne Hammill</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Oklahoma Health Sciences Center</name>
      <address>
        <city>Oklahoma City</city>
        <state>Oklahoma</state>
        <zip>73104</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Available</status>
    <contact>
      <phone>405-271-5311</phone>
    </contact>
    <investigator>
      <last_name>Janna Journeycake</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>The Childrens Hospital of Philadelphia</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19104</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Available</status>
    <investigator>
      <last_name>Denise Adams</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>LeBonheur Children's Medical Center</name>
      <address>
        <city>Memphis</city>
        <state>Tennessee</state>
        <zip>38103</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Available</status>
    <investigator>
      <last_name>Lucas Elijovich</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Monroe Carell Jr Childrens Hospital at Vanderbilt</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37232</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Available</status>
    <contact>
      <phone>615-321-5247</phone>
    </contact>
    <investigator>
      <last_name>Alexandra Borst</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Vanderbilt University Medical Center</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37232</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Available</status>
    <contact>
      <phone>615-322-5000</phone>
    </contact>
    <investigator>
      <last_name>Alexandra Borst</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Vanderbilt University Medical Center</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37232</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Available</status>
    <investigator>
      <last_name>Alexandra Borst</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Dell Childrens Medical Center of Central Texas</name>
      <address>
        <city>Austin</city>
        <state>Texas</state>
        <zip>78723</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Available</status>
    <investigator>
      <last_name>Donald Thomas Wells</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Texas Cancer Center ( Medical City Dallas Hospital)</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75230</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Available</status>
    <contact>
      <phone>972-566-7790</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>University of Texas Southwestern Medical Center</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75235-8858</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Available</status>
    <contact>
      <phone>214-648-2017</phone>
    </contact>
    <investigator>
      <last_name>Kathleen Ludwig</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Texas Southwestern Medical Center UT Southwestern</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75390-8852</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Available</status>
    <contact>
      <phone>214-645-4673</phone>
    </contact>
    <investigator>
      <last_name>Kathleen Ludwig</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>UT Southwestern Medical Center Pediatric Hematology/Onc</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75390</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Available</status>
    <contact>
      <phone>214-648-8594</phone>
    </contact>
    <investigator>
      <last_name>Kathleen Ludwig</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Texas Childrens Hospital CFTY720D2311</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Available</status>
    <contact>
      <phone>832-822-1804</phone>
    </contact>
    <investigator>
      <last_name>Ionela Iacobas</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Texas Childrens Hospital Oncology Department</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Available</status>
    <contact>
      <phone>832-824-4635</phone>
    </contact>
    <investigator>
      <last_name>Ionela Iacobas</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Texas Childrens Hospital</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Available</status>
    <contact>
      <phone>713-798-1204</phone>
    </contact>
    <investigator>
      <last_name>Ionela Iacobas</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>UVA Children s Hospital</name>
      <address>
        <city>Charlottesville</city>
        <state>Virginia</state>
        <zip>22903</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Available</status>
    <investigator>
      <last_name>William Petersen</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Children's Hospital of Richmond at VCU Pediatric Hematology Oncology</name>
      <address>
        <city>Richmond</city>
        <state>Virginia</state>
        <zip>23219</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Available</status>
    <contact>
      <phone>804-828-9605</phone>
    </contact>
    <investigator>
      <last_name>Kelly K Lastrapes</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Children's Hospital of Richmond at VCU</name>
      <address>
        <city>Richmond</city>
        <state>Virginia</state>
        <zip>23219</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Available</status>
    <contact>
      <phone>804-628-3093</phone>
    </contact>
    <investigator>
      <last_name>Janna Journeycake</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Virginia Mason Medical Center</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98101</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Available</status>
    <contact>
      <phone>206-223-6193</phone>
    </contact>
    <investigator>
      <last_name>Andrew Friedman</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Children's Hospital and Regional Medical Center</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98105-0371</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Available</status>
    <contact>
      <phone>206-528-5134</phone>
    </contact>
    <investigator>
      <last_name>Jonathan A Perkins</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Childrens Hospital of Wisconsin</name>
      <address>
        <city>Milwaukee</city>
        <state>Wisconsin</state>
        <zip>53226</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Available</status>
    <investigator>
      <last_name>Nathan Schloemer</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Midwest Children's Cancer Center</name>
      <address>
        <city>Milwaukee</city>
        <state>Wisconsin</state>
        <zip>53226</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Available</status>
    <investigator>
      <last_name>Nathan Schloemer</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Randwick</city>
        <state>New South Wales</state>
        <zip>2031</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Available</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Nedlands</city>
        <state>Western Australia</state>
        <zip>6009</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Available</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Brussel</city>
        <zip>1200</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Available</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Haine-saint-Paul</city>
        <zip>7100</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Available</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Quebec</city>
        <zip>G1R 2J6</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Available</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Quebec</city>
        <zip>H3T IC5</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Available</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Quebec</city>
        <country>Canada</country>
      </address>
    </facility>
    <status>Available</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Vancouver</city>
        <zip>V7L 2L7</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Available</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Zagreb</city>
        <zip>10000</zip>
        <country>Croatia</country>
      </address>
    </facility>
    <status>Available</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Helsinki</city>
        <zip>00290</zip>
        <country>Finland</country>
      </address>
    </facility>
    <status>Available</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Munich</city>
        <state>Bavaria</state>
        <country>Germany</country>
      </address>
    </facility>
    <status>Available</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Athens</city>
        <state>GR</state>
        <zip>151 23</zip>
        <country>Greece</country>
      </address>
    </facility>
    <status>Available</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Mumbai</city>
        <state>Maharashtra</state>
        <zip>400 053</zip>
        <country>India</country>
      </address>
    </facility>
    <status>Available</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Dublin 4</city>
        <zip>4</zip>
        <country>Ireland</country>
      </address>
    </facility>
    <status>Available</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Dublin</city>
        <zip>12</zip>
        <country>Ireland</country>
      </address>
    </facility>
    <status>Available</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Ramat Gan</city>
        <zip>52621</zip>
        <country>Israel</country>
      </address>
    </facility>
    <status>Available</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Durango</city>
        <zip>34000</zip>
        <country>Mexico</country>
      </address>
    </facility>
    <status>Available</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Nijmegen</city>
        <zip>6500 MB</zip>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Available</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Nijmegen</city>
        <zip>6525EX</zip>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Available</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Singapore</city>
        <zip>229899</zip>
        <country>Singapore</country>
      </address>
    </facility>
    <status>Available</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Ljubljana</city>
        <zip>1000</zip>
        <country>Slovenia</country>
      </address>
    </facility>
    <status>Available</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Oviedo</city>
        <state>Asturias</state>
        <zip>33011</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Available</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Barcelona</city>
        <state>Cataluna</state>
        <zip>08950</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Available</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Terrassa</city>
        <state>Catalunya</state>
        <zip>08221</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Available</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Madrid</city>
        <zip>28046</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Available</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Zuerich</city>
        <zip>CH - 8032</zip>
        <country>Switzerland</country>
      </address>
    </facility>
    <status>Available</status>
  </location>
  <location_countries>
    <country>Australia</country>
    <country>Belgium</country>
    <country>Canada</country>
    <country>Croatia</country>
    <country>Finland</country>
    <country>Germany</country>
    <country>Greece</country>
    <country>India</country>
    <country>Ireland</country>
    <country>Israel</country>
    <country>Mexico</country>
    <country>Netherlands</country>
    <country>Singapore</country>
    <country>Slovenia</country>
    <country>Spain</country>
    <country>Switzerland</country>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2021</verification_date>
  <study_first_submitted>September 5, 2019</study_first_submitted>
  <study_first_submitted_qc>September 5, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">September 11, 2019</study_first_posted>
  <last_update_submitted>May 6, 2021</last_update_submitted>
  <last_update_submitted_qc>May 6, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">May 7, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>adult</keyword>
  <keyword>pediatric</keyword>
  <keyword>BYL719</keyword>
  <keyword>PIK3CA</keyword>
  <keyword>Overgrowth Spectrum</keyword>
  <keyword>PROS</keyword>
  <keyword>alpelisib</keyword>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

